S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

KURA Kura Oncology Inc

11.21

0.01 (0.09%)

Last Updated: 10:47:21

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/18/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

06/10/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ UBS Financial Services Inc, as attorney-in-fact for Kathleen Ford

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Kura Oncology Charts.

Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Kura Oncology Charts.

Kura Oncology Inc News

Kura Oncology to Host Virtual Investor Event on December 9, 2024
Monday 2 December 2024 (1 day ago) • GlobeNewswire Inc.

Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Monday 25 November 2024 (1 week ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 20 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Wednesday 20 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Monday 18 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Thursday 7 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 7 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Kura Oncology Reports Third Quarter 2024 Financial Results
Thursday 7 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Tuesday 5 November 2024 (4 weeks ago) • GlobeNewswire Inc.

Kura Oncology to Report Third Quarter 2024 Financial Results
Thursday 31 October 2024 (1 month ago) • GlobeNewswire Inc.

Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)
Thursday 24 October 2024 (1 month ago) • GlobeNewswire Inc.

More Kura Oncology Inc News Articles

Impact Fusion (PK)

Bioelectronics (PK)

TPT Global Tech (CE)

Kraig Biocraft Laborator... (QB)

Accredited Solutions (PK)

Fannie Mae (QB)

CyberFuels (PK)

Rennova Health (CE)

North Bay Resources (PK)

Moon Equity (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions